#HotTopics in #TargetedTherapies also covered at #ccfac2024 .

👉🏼Resistance to FGFR inhibitors: #tinengotinib

👉🏼New targets: #brigimadlin for #MDM2 amplification

The future looks brighter. #CCAhope

Angela Lamarca Mitesh Borad, M.D.

A meta-analysis of the physical and mental health benefits of touch interventions | Nature Human Behaviour. Interesting study to show health care benefits of touch- greatly affected by the pandemic. Physical contact is still key! nature.com/articles/s4156…

Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma | JCO Precision Oncology ascopubs.org/doi/10.1200/PO… Congratulations Shalini Makawita for your important work in IDH altered CCA Cholangiocarcinoma Foundation ENSCCA_2020 MD Anderson Cancer Center

Enhertu Gets Tumor-Agnostic FDA Approval for HER2-Positive Cancers | MedPage Today. Exciting news for GI cancers including BTC and CRC ⁦Cholangiocarcinoma Foundation⁩ ⁦ENSCCA_2020⁩ ⁦MD Anderson Cancer Center⁩ medpagetoday.com/hematologyonco…

sciencedirect.com/science/articl…
Congratulations @Amol Patel for your publication. Cholangiocarcinoma Foundation ENSCCA_2020 IHPBA

The Houston sky is so blue this morning.

What can one say, when you work with the best team ever! Much 💚and happy doctors day y’all

“We are hoping that this work will lead to subsequent approval of therapeutic options for patients who have stopped responding to the first-line treatments,” says our Milind Javle of a new type of FGFR inhibitor to treat bile duct cancer. brnw.ch/21wHMgl #EndCancer

Congratulations Hop S. Tran Cao for leading this important trial for our patients with #cholangiocarcinoma . Important study! 👏👏👏👏💥💥💥💥 #oncsurgery #endcancer MD Anderson Cancer Center Milind Javle Cholangiocarcinoma Foundation

Why Even Public Health Experts Have Limited Insight Into Stopping Gun Violence in America - KFF Health News kffhealthnews.org/news/article/g…

Hear the latest strategies to develop individualized treatment plans for your patients with advanced #BiliaryTractCancers , from experts Milind Javle, @GIcancerdoc, & Rachna Shroff, MD, FASCO, and our partner, PeerView.

bit.ly/4362jGX #Oncology #GI24 #MedEd #MedTwitter

Some of my office orchids back ⁦Dr. Dr. Helene Andrews-Polymenis,⁩ but others await spring? This one is a hearty recommendation ⁦AOS⁩ ⁦Heart of Texas Orchid Society⁩

Cholangiocarcinoma Awareness Month
Cholangiocarcinoma Foundation MD Anderson Cancer Center Milind Javle Cholangiocarcinoma Foundation Global Cholangiocarcinoma Alliance

Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors - PMC ncbi.nlm.nih.gov/pmc/articles/P…

#OpenAccess in Cancer Discovery from Dr. Funda Meric MD Anderson Cancer Center
Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts
aacrjournals.org/cancerdiscover…
This study also found MET amplification as a resistance mechanism to Her-2 bispecifics. Good…

NALIRIFOX approved as front line option🫶🏽. The question I have is will this serve as proxy data for reducing the dose of oxaliplatin in FOLFIRINOX regimen to help neuropathy and tolerance Dr. jordan berlin Eileen M O’Reilly Milind Javle Efrat Dotan MD Kim Reiss Binder (Kim Reiss)

How common are MTAP deletions in advanced GI cancers? What are the molecular correlates of MTAP loss? In this large study (>64K tumors) conducted in partnership with Foundation Medicine, MD Anderson Cancer Center investigators (@NatalieNgoi Jordi Rodon) find 1 in 5 #PancreaticCancer cases…

Lucky to have Milind Javle #cholangiocarcinoma expert visiting Winship Cancer Institute of Emory University Emory University to educate on this orphan cancer! Cholangiocarcinoma Foundation Emory Gastroenterology and Hepatology Fellowship